Project Grant R01AI195920
Award Date 8/4/26
Completion Date 7/31/31
Dollars Obligated $796K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30303, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $197,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate cross-protective immune mechanisms of combined mRNA and conventional influenza vaccines. The research develops new mRNA vaccine constructs encoding neuraminidase conjugated to a conserved M2E repeat, designed to enhance broad cross-protection against different...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $1,023,862 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to produce and distribute filarial research reagents through the Filariasis Research Reagent Resource Center (FR3). The award funds three specific aims over a five-year period ending August 31, 2031. Under Aim 1, the recipient will ensure continued provision of high-quality...
- The National Institute of Allergy and Infectious Diseases awarded Georgia State University Research Foundation Inc. $197,552 on August 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a novel nanoplatform for nasal universal influenza vaccines. The project addresses limitations in current cross-protective influenza vaccines by creating a nasal delivery system using nanosized extracellular vesicles (EVs) that display inverted hemagglutinin (HA)...
- The National Institute of Allergy and Infectious Diseases awarded $157,356 to the University of Georgia Research Foundation, Inc. on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct strain-resolved metagenomics analysis of Bifidobacterium infantis colonization in early infancy and its associations with child health outcomes. The research generates shotgun metagenome data from biobanked infant stool samples collected through the ECOMID birth...
- The National Institute of Allergy and Infectious Diseases awarded $400,932 to the University of Georgia Research Foundation, Inc. on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into immunity induced by cryptococcal morphological strains in CD4+ T cell-deficient hosts. The research addresses cryptococcal meningoencephalitis, which accounts for more than 15 percent of total AIDS-related deaths globally, with mortality rates...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $161,244 on April 16, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct experimental evolution assays elucidating evolutionary trajectories to antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, and how the immune system modifies these trajectories. The research uses in vivo adaptive laboratory evolution experiments in Galleria...
- The National Institute of Allergy and Infectious Diseases awarded the University of Georgia Research Foundation $228,000 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop enzymatic pipelines for the in vitro synthesis of parasitic glycosylphosphatidylinositol (GPI) anchors and GPI-anchored proteins. Parasitic infections affect more than one billion people globally. GPI anchors and GPI-anchored proteins are essential to parasite cell surfaces and...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $773,388 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to decode the cellular networks governing respiratory mucosal IgA immunity. The research addresses mechanisms driving robust respiratory mucosal immunity, particularly IgA responses following infection or vaccination, with the goal of informing next-generation mucosal vaccine strategies against...
- The National Institute of Allergy and Infectious Diseases awarded Emory University $100,228 on September 30, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the regulatory mechanisms controlling sporulation, motility, and virulence in spore-forming bacteria. The project focuses on the role of SPO0E, a conserved regulatory protein that controls the transition from vegetative bacterial cells to dormant spores in Bacilli and Clostridia species. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $790,913 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the molecular and cellular mechanisms by which gut commensal microbiota-specific T cells drive intestinal and neuroinflammation. The project investigates how segmented filamentous bacteria (SFB)-specific CD4 T cells, initially generated in gut-draining mesenteric lymph nodes and intestines in...